一线帕博利珠单抗联合化疗治疗晚期非小细胞肺癌的肿瘤负荷动态与生存
研究纳入133例接受一线帕博利珠单抗联合铂双药化疗的晚期NSCLC患者,通过系列CT评估肿瘤负荷动态与总生存(OS)的关系。结果显示,治疗前8周肿瘤负荷低于基线者OS显著延长(中位OS 26.8 vs 7.6个月,HR 0.36,p<0.001),全程负荷持续低于基线者死亡风险降低(HR 0.72,p=0.03)。假性进展仅0.8%。
要点
- 治疗前8周CT示肿瘤负荷低于基线是OS延长的影像标志(中位OS 26.8 vs 7.6个月)。
- 全程肿瘤负荷持续低于基线者死亡风险显著降低(HR 0.72,p=0.03)。
- 假性进展发生率仅0.8%,提示该现象罕见但需警惕。
核心结论
- 全程肿瘤负荷持续低于基线可预测一线帕博利珠单抗联合化疗的晚期NSCLC患者OS延长。
研究设计与样本
- 单中心回顾性研究,纳入133例接受一线帕博利珠单抗联合铂双药化疗的晚期NSCLC患者,分析系列CT扫描的肿瘤负荷动态与OS关联。
关键影像表现/征象
- 最佳总缓解时肿瘤负荷变化范围为-100.0%至+132.1%(中位-30%)。
- 仅1例(0.8%)出现假性进展。
诊断标准与关键数值
- 采用8周里程碑分析,前8周肿瘤负荷低于基线者较≥0%增长者OS更长(中位OS 26.8 vs 7.6个月,HR 0.36,p<0.001)。
- 校正其他临床变量后,全程肿瘤负荷低于基线者死亡风险显著降低(HR 0.72,p=0.03)。
临床应用与阅片要点
- 系列CT随访中应关注肿瘤负荷相对于基线的动态变化,而非仅依据RECIST判定缓解。
- 治疗前8周内肿瘤负荷未低于基线提示预后较差,可辅助治疗决策。
局限性
- 单中心回顾性设计,结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The study investigated tumor burden dynamics on computed tomography (CT) scans in patients with advanced non-small-cell lung cancer (NSCLC) during first-line pembrolizumab plus chemotherapy, to provide imaging markers for overall survival (OS).
METHODS: The study included 133 patients treated with first-line pembrolizumab plus platinum-doublet chemotherapy. Serial CT scans during therapy were assessed for tumor burden dynamics during therapy, which were studied for the association with OS.
RESULTS: There were 67 responders, with overall response rate of 50%. The tumor burden change at the best overall response ranged from - 100.0% to + 132.1% (median of - 30%). Higher response rates were associated with younger age (p < 0.001) and higher programmed cell death-1 (PD-L1) expression levels (p = 0.01). Eighty-three patients (62%) showed tumor burden below the baseline burden throughout therapy. Using an 8-week landmark analysis, OS was longer in patients with tumor burden below the baseline burden in the first 8 weeks than in those who experienced ≥ 0% increase (median OS: 26.8 vs. 7.6 months, hazard ratio (HR): 0.36, p < 0.001). Tumor burden remained below their baseline throughout therapy was associated with significantly reduced hazards of death (HR: 0.72, p = 0.03) in the extended Cox models, after adjusting for other clinical variables. Pseudoprogression was noted in only one patient (0.8%).
CONCLUSIONS: Tumor burden staying below the baseline burden throughout the therapy was predictive of prolonged overall survival in patients with advanced NSCLC treated with first-line pembrolizumab plus chemotherapy, and may be used as a practical marker for therapeutic decisions in this widely used combination regimen.
CLINICAL RELEVANCE STATEMENT: The analysis of tumor burden dynamics on serial CT scans in reference to the baseline burden can provide an additional objective guide for treatment decision making in patients treated with first-line pembrolizumab plus chemotherapy for their advanced NSCLC.
KEY POINTS: • Tumor burden remaining below baseline burden during therapy predicted longer survival during first-line pembrolizumab plus chemotherapy. • Pseudoprogression was noted in 0.8%, demonstrating the rarity of the phenomenon. • Tumor burden dynamics may serve as an objective marker for treatment benefit to guide treatment decisions during first-line pembrolizumab plus chemotherapy.
引用
- Nishino, Wang, Ricciuti, et al. Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. Eur Radiol. 2023. PMID: 37099174. doi:10.1007/s00330-023-09658-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。